*Project – 2019 Global Core Research

2019 ISAR Global Research Project 

What is the effectiveness of biologics by class in patients eligible for both modalities?

  • To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
  • To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, lung function

Prof. David Price (Singapore)

ADEPT:

ENCePP: